Trial Profile
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Lung cancer; Malignant melanoma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 22 Sep 2022 Planned End Date changed from 31 Mar 2024 to 1 Apr 2024.
- 22 Sep 2022 Planned primary completion date changed from 31 Mar 2024 to 1 Apr 2024.
- 24 Feb 2022 Planned End Date changed from 31 Dec 2024 to 31 Mar 2024.